Dr Ana Milosevic
contactpointnano.ch, Empa


The national contactpointnano.ch for safe handling, regulation and transfer of nanomaterials?


As an independent national contact point, contactpointnano.ch pools and structures the scientific and regulatory expertise available in Switzerland on the safe handling of synthetic nanomaterials – from production and application to disposal. Its objective is to efficiently convey tailored high-quality information to companies (established companies, SMEs and start-ups), thus accelerating the transfer from invention to innovation and allowing Swiss companies to remain competitive in an international environment. contactpointnano.ch is based on a broad network of proven experts and ensures a qualified and independent transfer of knowledge. It anticipates topics for regular workshops on current matters, organizes information events and facilitates the exchange of experience and know-how in the area of innovation and safe by design, and the evolution of Swiss and international regulatory framework.

contactpointnano.ch provides tailored contacts to experts who: i) can convey information on nanomaterials, their safe handling as well as relevant regulatory provisions, ii) offer expert opinions and procure access to services, testing and analyses, iii) are active in the field of research and development. At contactpointnano.ch companies will find competent partners who will assist them directly or point them to available knowledge resources and agencies.


Ana Milosevic obtained her MSc degree in Biochemistry at Faculty of Chemistry, University of Belgrade. In 2018 she completed her PhD studies at the Adolphe Merkle Institute, University of Fribourg, in the group of Prof. Barbara Rothen Rutishauser and Prof. Alke Fink where she worked with fluorescently labelled nanoparticles and investigated their interaction with cell and ultimate fate. Currently she is a project manager for the national contactpoint-nano.ch for the safe handling of nanomaterials, regulation and knowledge transfer.